Testing the relationships between balancing selection and deleterious genetic mutations in four endangered species of whale

Although small and isolated populations experience increased extinction risk, recent research shows that not all small populations are doomed to extinction. The ability to predict the probability of extinction in nature could therefore direct conservation resources to those populations most in need. One theory is that small populations can evade extinction when directional selection removes […]

Read More
L2M – Validate, ComfiDam

This project will help evaluate the market for ComfiDam, a breathable rubber dam that makes dental procedures safer and more comfortable for patients. Rubber dams are considered mandatory for root canal procedures, which are performed over 15 million times each year in the United States, essential for infection control and patient safety. However, their adoption […]

Read More
L2M – Antioxidant-rich Functional Fiber Developed from Co-products of Cereals and Legumes

Antioxidant dietary fiber is an emerging concept that combines the health benefits of dietary fiber and natural polyphenolic antioxidants into a single functional ingredient. Dietary fiber supports gut and heart health, blood sugar regulation, weight management, and digestive well-being. Phenolic compounds, commonly found in colorful fruits and vegetables, help protect the body from oxidative damage […]

Read More
L2M — Development and Validation of a Novel Pain-Conscious Tool for IUD and Endometrial Biopsy Procedures

This project supports the development of an innovative device that makes IUD insertions and endometrial biopsies less painful and more accurate. By replacing outdated tools with one integrated system, it improves patient comfort and clinical efficiency. The project will provide ReFem Technologies with real-world feedback, regulatory insights, and a clear path to market, accelerating the […]

Read More
L2M Launch / Qc Fall 2025 / Espoir Biosciences

Ce projet vise à transformer une découverte scientifique prometteuse en une entreprise biotechnologique dédiée au développement d’un traitement innovant contre la sclérose latérale amyotrophique (SLA), une maladie neurodégénérative incurable. Issu du laboratoire du Dr Alex Parker au CRCHUM, le traitement proposé repose sur un mécanisme inédit de régénération des neurones endommagés. Les traitements actuellement disponibles […]

Read More
L2M Validation/ Qc Automne 2025 / NeuroMouv-Affectome

Le projet vise à explorer comment la danse peut aider les personnes âgées à préserver leurs capacités cognitive et leur équilibre. La stagiaire réalisera une première étude pilote pour tester les effets immédiats d’une séance de danse sur la cognition et les capacités fonctionelles. Ce protocole représente une phase de démarrage, qui servira à poser […]

Read More
L2M – Health Validate – A Rapid and Portable DNAzyme-Based Biosensor for Early Colorectal Cancer Detection

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in Canada, with over 24,000 new cases and 9,300 deaths reported in 2023. Early detection significantly improves survival rates, yet current screening methods, such as stool-based tests and colonoscopies, have major limitations. Fecal tests often produce false positives, leading to unnecessary and invasive colonoscopies, […]

Read More
L2M Validation / Qc Fall 2025 / DeepScript

This project will support the development of DeepScript, a software platform that helps researchers find promising small molecules for drug discovery without needing to run large and expensive screening campaigns. Instead of testing hundreds of thousands of compounds, DeepScript uses biological data and artificial intelligence to predict which existing compounds are most likely to work […]

Read More
Modeling cardiac fibrosis in a dish with human iPSC-derived fibroblasts

Cardiovascular disease remains a leading cause of death in Canada and is a progressive disease characterized by impaired heart function that can ultimately lead to heart failure, with a rising incidence and a 5-year survival rate of only 50%. Advanced cases of heart failure caused by dilated cardiomyopathy (DCM) are referred for mechanical circulatory support […]

Read More
L2M Launch / Qc Fall 2025 / mTatt

mTatt is a medtech startup developing functional microtattoos for real-time, at-home health monitoring. Using dissolving microneedles — biocompatible structures under 1 mm in length — we painlessly deliver fluorescent sensors into the skin, creating a functional tattoo. These sensors respond to key biomarkers like NT-proBNP, glucose, or electrolytes, providing clinically valuable insights without blood draws […]

Read More
Development of rapid and accurate genomic techniques for ballast water UV treatment

The United States Coast Guard (USCG) recently introduced stringent regulations for the treatment of ballast water. Ultra-violet (UV) light is a useful technology in a ballast water treatment system (BWTS), for inactivating species which could be invasive and harmful to humans and the environment. UV damages DNA and prevents replication, but the vital stain methods […]

Read More